Phil Bardwell

Phil Bardwell is an accomplished professional in the field of translational sciences and oncology drug development. Currently serving as Executive Director of Translational Sciences at Ottimo Pharma and as a Consultant at PDB Consulting-Biomarkers, Phil focuses on early clinical phase solid tumor oncology drug development programs. Previous roles include Senior Director of Translational Sciences at Adaptimmune and Senior Director at TCR² Therapeutics Inc. Phil has extensive experience in clinical biomarkers and immuno-oncology, having held pivotal positions at Repertoire Immune Medicines, Torque, and AbbVie Bioresearch Center. Phil holds a Ph.D. in Immunology from Albert Einstein College of Medicine and a B.S. in Biochemistry & Cell Biology from UC San Diego.